Sitaxsentan ICOS-Texas Biotechnology

Current Opinion in Investigational Drugs

Volumn 2, Issue 4, 2001, Pages 531-536

  Wu Wong, J R ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 7 [2 (2 CARBOXYPROPYL ) 4 METHOXYPHENYL] 5 (3,4 METHYLENEDIOXYPHENYL)CYCLOPENTENO[1,2 B]PYRIDINE 6 CARBOXYLIC ACID; 27 O [3 [2 (3 CARBOXYACRYLOYLAMINO) 5 HYDROXYPHENYL]ACRYLOYLOXY]MYRICERONE; BMS 193884; BOSENTAN; DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST; IPI 1040; IPI 1251; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; PHOSPHATIDYLINOSITIDE; PLACEBO; SITAXSENTAN; TBC 11241; TEZOSENTAN; UNCLASSIFIED DRUG;

CHEMICAL MODIFICATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; EXERCISE TOLERANCE; EXPERIMENTAL MODEL; FETUS DEVELOPMENT; HEART HYPERTROPHY; HUMAN; NONHUMAN; PROSTATE CANCER; PULMONARY HYPERTENSION; RECEPTOR BLOCKING; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; SUBARACHNOID HEMORRHAGE; TOXICITY TESTING; VASCULAR RESISTANCE;

ANIMALS; CLINICAL TRIALS; HEART FAILURE, CONGESTIVE; HUMANS; ISOXAZOLES; LUNG DISEASES, OBSTRUCTIVE; RECEPTOR, ENDOTHELIN A; RECEPTORS, ENDOTHELIN; SUBARACHNOID HEMORRHAGE; THIOPHENES;

EID: 0035043336     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Update on endothelin research
2. A selective endothelin antagonists
3. A selective endothelin antagonist
4. A selective endothelin antagonists
5. A selective endothelin antagonists
6. Drug development pipeline
7. Texas Biotechnology announces strategic alliance with LG Chem; LG Chem to market two TBC therapeutics in Asia, excluding Japan
8. Texas Biotechnology announces initiation of phase I clinical trial for TBC-11251 to treat congestive heart failure
9. Clinical trials update
10. Texas Biotechnology receives US patents for new class of cardiovascular therapeutics, endothelin A receptor antagonists
11. Endothelin receptors: Receptor classification, novel receptor antagonists, and potential therapeutic targets
12. Structure-activity relationships of N2-aryl-3-(isoxazolysulfamoyl)-2-thiophenecarboxamides as selective endothelin receptor-A antagonists 1
13. Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist 1
14. Cardiopulmonary indications for endothelin receptor antagonists: Review of recent efficacy trials
15. TBC11251, a highly selective endothelin-A receptor antagonist, prevents and reverses acute hypoxia-induced pulmonary hypertension in the rat
16. Endothelin inhibitors; Advances in Therapeutic Application and Development IBC's Third International Symposium, Philadelphia, USA
17. Endothelins: Roles in pulmonary diseases, ATS/ALA Annual Meeting, San Francisco, CA, USA
18. A selective endothelin receptor antagonists
19. Texas Biotechnology completes phase I safety trial for oral endothelin antagonist
20. Endothelin in the pulmonary circulation with special reference to hypoxic pulmonary vasoconstriction
21. Texas Biotechnology reports positive phase IIa trial results of endothelin receptor antagonist in CHF
22. Clinical trials update
23. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
24. The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes
25. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1
26. IBC's Conference on Pulmonary Hypertension: New Understanding for Therapeutic Development
27. Texas Biotechnology updates stockholders at 1998 annual meeting
28. COPD: New Developments and Therapeutic Opportunities, National Heart and Lung Institute, London, UK
29. Texas Biotechnology reports additional positive phase IIA trial results in congestive heart failure
30. Endothelium-dependent changes in retinal blood flow following ischemia
31. The endothelin system: A novel therapeutic target in cardiovascular disease
32. Drug development pipeline
33. Texas Biotechnology reports progress on endothelin A receptor antagonist program
34. A receptors
35. ICOS and Texas Biotechnology establish joint venture to develop and commercialize endothelin antagonists
36. Endothelin receptor antagonists: A clinical study update
37. American Heart Association 73rd Scientific Sessions - Overnight report (Part II), New Orleans, LA, USA
38. Oral sitaxsentan, an endothelin-A selective receptor antagonist, reduces systemic blood pressure in patients with mild-to-moderate primary hypertension
39. Efficacy and safety of chronic treatment with oral selective endothelin-A-receptor blocker sitaxsentan in pulmonary arterial hypertension
40. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure
41. A receptor antagonist
42. ICOS and Texas Biotechnology initiate human testing with TBC3711, a second highly selective endothelin a receptor antagonist